The Prognostic Value of Serum Biomarkers in Osteosarcoma

NCT05093101 | Completed

• 1 other identifier: ProOsteo
• Study Type: observational
• Target: 600
• Locations: 1 country
• Sites: 1

Brief Summary

Observational retrospective cohort study using laboratory data of blood tests prior to surgical and chemotherapy treatment and other histologic, clinical, and instrumental data related to patient history from digitized medical records and analysis of the same as predictors of outcomes.

Conditions

Osteosarcoma

Outcome Measures

Primary Outcomes (1)

• Evaluation of 5-year survival

  Evaluation of 5-year survival in relation to histologic, laboratory, clinical, and instrumental prognostic factors

  5 years

Secondary Outcomes (1)

• Evaluation of the rate of local recurrence

  5 years

Interventions

case series review of clinical data OTHER

Extraction of pre-surgical and chemotherapy blood test laboratory data and clinical and instrumental data related to patient history from digitized medical records and analysis

Eligibility Criteria

• Age: 2 Years+
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

pazients with osteosarcoma from 01-01-2000 to 31-12-2020

You may qualify if:

• Osteosarcoma diagnosed at the Pathological Anatomy of the Rizzoli Orthopaedic Institute in Bologna;
• Minimum 2-year follow-up period;
• Medical records, complete blood work and instrumental examinations, regular follow-up;
• Patients with age ≥ 2 years;

You may not qualify if:

• Patients with osteosarcoma who have received medical treatment (surgery, radiotherapy or chemotherapy) in other hospitals prior to admission to our Institute

Sponsors & Collaborators

• Istituto Ortopedico Rizzoli: lead

Study Sites (1)

IRCCS Itituto Ortopedico Rizzoli

Bologna, BO, 40136, Italy

Location

Related Publications (4)

• Nakamura T, Grimer RJ, Gaston CL, Watanuki M, Sudo A, Jeys L. The prognostic value of the serum level of C-reactive protein for the survival of patients with a primary sarcoma of bone. Bone Joint J. 2013 Mar;95-B(3):411-8. doi: 10.1302/0301-620X.95B3.30344.

  PMID: 23450030 RESULT

• Li YJ, Yang X, Zhang WB, Yi C, Wang F, Li P. Clinical implications of six inflammatory biomarkers as prognostic indicators in Ewing sarcoma. Cancer Manag Res. 2017 Sep 28;9:443-451. doi: 10.2147/CMAR.S146827. eCollection 2017.

  PMID: 29033609 RESULT

• Aggerholm-Pedersen N, Maretty-Kongstad K, Keller J, Baerentzen S, Safwat A. The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma. Transl Oncol. 2016 Aug;9(4):322-8. doi: 10.1016/j.tranon.2016.05.006.

  PMID: 27567955 RESULT

• Basoli S, Cosentino M, Traversari M, Manfrini M, Tsukamoto S, Mavrogenis AF, Bordini B, Donati DM, Errani C. The Prognostic Value of Serum Biomarkers for Survival of Children with Osteosarcoma of the Extremities. Curr Oncol. 2023 Jul 24;30(7):7043-7054. doi: 10.3390/curroncol30070511.

  PMID: 37504371 DERIVED

MeSH Terms

Conditions

Osteosarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Bone Tissue; Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 12, 2021
• First Posted: October 26, 2021
• Study Start: July 12, 2021
• Primary Completion: December 22, 2021
• Study Completion: December 22, 2021
• Last Updated: April 5, 2022

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)